Foghorn Therapeutics to Present New Preclinical Data for BRG1/BRM Inhibitor FHD-286 in Combination with Anti-PD-1 Antibody at Society for Immunotherapy of Cancer 37th Annual Meeting
Foghorn Therapeutics Inc. (FHTX)
Company Research
Source: GlobeNewswire
CAMBRIDGE, Mass., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced new preclinical data for its FHD-286 program will be highlighted in a poster presentation at the Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting. The meeting will be held November 8–12, 2022, at the Boston Convention and Exhibition Center and virtually. New preclinical data will be presented on FHD-286, a potent and selective BRG1/BRM inhibitor, which is currently in Phase 1 clinical trials for the treatment of metastatic uveal melanoma (UM) and for relapsed and/or refractory acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS). The poster will highlight new data demonstrating the potential of FHD-286, in combination with an anti-PD-1 antibody, to provide synergistic efficacy and survival benefit comp
Show less
Read more
Impact Snapshot
Event Time:
FHTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
FHTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
FHTX alerts
High impacting Foghorn Therapeutics Inc. news events
Weekly update
A roundup of the hottest topics
FHTX
News
- Foghorn Therapeutics Strengthens Financial Leadership with Appointment of Kristian Humer as Chief Financial Officer [Yahoo! Finance]Yahoo! Finance
- Foghorn Therapeutics Strengthens Financial Leadership with Appointment of Kristian Humer as Chief Financial OfficerGlobeNewswire
- Foghorn Therapeutics Inc. (NASDAQ: FHTX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $20.00 price target on the stock.MarketBeat
- Foghorn Therapeutics Inc. (NASDAQ: FHTX) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $13.00 price target on the stock.MarketBeat
- Foghorn Therapeutics Presents New Preclinical Data on Potential First-in-Class BRM Selective Inhibitor FHD-909 and Selective CBP and Selective EP300 Degrader Oncology Programs [Yahoo! Finance]Yahoo! Finance
FHTX
Earnings
- 8/4/23 - Beat
FHTX
Sec Filings
- 4/17/24 - Form 4
- 4/17/24 - Form 3
- 4/16/24 - Form 8-K
- FHTX's page on the SEC website